Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study

EH. Martinez-Lapiscina, S. Arnow, JA. Wilson, S. Saidha, JL. Preiningerova, T. Oberwahrenbrock, AU. Brandt, LE. Pablo, S. Guerrieri, I. Gonzalez, O. Outteryck, AK. Mueller, P. Albrecht, W. Chan, S. Lukas, LJ. Balk, C. Fraser, JL. Frederiksen, J....

. 2016 ; 15 (6) : 574-84. [pub] 20160318

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc17024099
E-zdroje Online Plný text

NLK ProQuest Central od 2002-05-01 do Před 2 měsíci
Nursing & Allied Health Database (ProQuest) od 2002-05-01 do Před 2 měsíci
Health & Medicine (ProQuest) od 2002-05-01 do Před 2 měsíci
Psychology Database (ProQuest) od 2002-05-01 do Před 2 měsíci

Odkazy

PubMed 27011339
DOI 10.1016/s1474-4422(16)00068-5
Knihovny.cz E-zdroje

BACKGROUND: Most patients with multiple sclerosis without previous optic neuritis have thinner retinal layers than healthy controls. We assessed the role of peripapillary retinal nerve fibre layer (pRNFL) thickness and macular volume in eyes with no history of optic neuritis as a biomarker of disability worsening in a cohort of patients with multiple sclerosis who had at least one eye without optic neuritis available. METHODS: In this multicentre, cohort study, we collected data about patients (age ≥16 years old) with clinically isolated syndrome, relapsing-remitting multiple sclerosis, and progressive multiple sclerosis. Patients were recruited from centres in Spain, Italy, France, Germany, Czech Republic, Netherlands, Canada, and the USA, with the first cohort starting in 2008 and the latest cohort starting in 2013. We assessed disability worsening using the Expanded Disability Status Scale (EDSS). The pRNFL thickness and macular volume were assessed once at study entry (baseline) by optical coherence tomography (OCT) and was calculated as the mean value of both eyes without optic neuritis for patients without a history of optic neuritis or the value of the non-optic neuritis eye for patients with previous unilateral optic neuritis. Researchers who did the OCT at baseline were masked to EDSS results and the researchers assessing disability with EDSS were masked to OCT results. We estimated the association of pRNFL thickness or macular volume at baseline in eyes without optic neuritis with the risk of subsequent disability worsening by use of proportional hazards models that included OCT metrics and age, disease duration, disability, presence of previous unilateral optic neuritis, and use of disease-modifying therapies as covariates. FINDINGS: 879 patients with clinically isolated syndrome (n=74), relapsing-remitting multiple sclerosis (n=664), or progressive multiple sclerosis (n=141) were included in the primary analyses. Disability worsening occurred in 252 (29%) of 879 patients with multiple sclerosis after a median follow-up of 2·0 years (range 0·5-5 years). Patients with a pRNFL of less than or equal to 87 μm or less than or equal to 88 μm (measured with Spectralis or Cirrus OCT devices) had double the risk of disability worsening at any time after the first and up to the third years of follow-up (hazard ratio 2·06, 95% CI 1·36-3·11; p=0·001), and the risk was increased by nearly four times after the third and up to the fifth years of follow-up (3·81, 1·63-8·91; p=0·002). We did not identify meaningful associations for macular volume. INTERPRETATION: Our results provide evidence of the usefulness of monitoring pRNFL thickness by OCT for prediction of the risk of disability worsening with time in patients with multiple sclerosis. FUNDING: Instituto de Salud Carlos III.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17024099
003      
CZ-PrNML
005      
20170831102536.0
007      
ta
008      
170720s2016 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/S1474-4422(16)00068-5 $2 doi
035    __
$a (PubMed)27011339
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Martinez-Lapiscina, Elena H $u Institut d'Investigacions Biomèdiques August Pi Sunyer (IDIBAPS), Barcelona, Spain.
245    10
$a Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study / $c EH. Martinez-Lapiscina, S. Arnow, JA. Wilson, S. Saidha, JL. Preiningerova, T. Oberwahrenbrock, AU. Brandt, LE. Pablo, S. Guerrieri, I. Gonzalez, O. Outteryck, AK. Mueller, P. Albrecht, W. Chan, S. Lukas, LJ. Balk, C. Fraser, JL. Frederiksen, J. Resto, T. Frohman, C. Cordano, I. Zubizarreta, M. Andorra, B. Sanchez-Dalmau, A. Saiz, R. Bermel, A. Klistorner, A. Petzold, S. Schippling, F. Costello, O. Aktas, P. Vermersch, C. Oreja-Guevara, G. Comi, L. Leocani, E. Garcia-Martin, F. Paul, E. Havrdova, E. Frohman, LJ. Balcer, AJ. Green, PA. Calabresi, P. Villoslada, . ,
520    9_
$a BACKGROUND: Most patients with multiple sclerosis without previous optic neuritis have thinner retinal layers than healthy controls. We assessed the role of peripapillary retinal nerve fibre layer (pRNFL) thickness and macular volume in eyes with no history of optic neuritis as a biomarker of disability worsening in a cohort of patients with multiple sclerosis who had at least one eye without optic neuritis available. METHODS: In this multicentre, cohort study, we collected data about patients (age ≥16 years old) with clinically isolated syndrome, relapsing-remitting multiple sclerosis, and progressive multiple sclerosis. Patients were recruited from centres in Spain, Italy, France, Germany, Czech Republic, Netherlands, Canada, and the USA, with the first cohort starting in 2008 and the latest cohort starting in 2013. We assessed disability worsening using the Expanded Disability Status Scale (EDSS). The pRNFL thickness and macular volume were assessed once at study entry (baseline) by optical coherence tomography (OCT) and was calculated as the mean value of both eyes without optic neuritis for patients without a history of optic neuritis or the value of the non-optic neuritis eye for patients with previous unilateral optic neuritis. Researchers who did the OCT at baseline were masked to EDSS results and the researchers assessing disability with EDSS were masked to OCT results. We estimated the association of pRNFL thickness or macular volume at baseline in eyes without optic neuritis with the risk of subsequent disability worsening by use of proportional hazards models that included OCT metrics and age, disease duration, disability, presence of previous unilateral optic neuritis, and use of disease-modifying therapies as covariates. FINDINGS: 879 patients with clinically isolated syndrome (n=74), relapsing-remitting multiple sclerosis (n=664), or progressive multiple sclerosis (n=141) were included in the primary analyses. Disability worsening occurred in 252 (29%) of 879 patients with multiple sclerosis after a median follow-up of 2·0 years (range 0·5-5 years). Patients with a pRNFL of less than or equal to 87 μm or less than or equal to 88 μm (measured with Spectralis or Cirrus OCT devices) had double the risk of disability worsening at any time after the first and up to the third years of follow-up (hazard ratio 2·06, 95% CI 1·36-3·11; p=0·001), and the risk was increased by nearly four times after the third and up to the fifth years of follow-up (3·81, 1·63-8·91; p=0·002). We did not identify meaningful associations for macular volume. INTERPRETATION: Our results provide evidence of the usefulness of monitoring pRNFL thickness by OCT for prediction of the risk of disability worsening with time in patients with multiple sclerosis. FUNDING: Instituto de Salud Carlos III.
650    _2
$a dospělí $7 D000328
650    _2
$a kohortové studie $7 D015331
650    12
$a progrese nemoci $7 D018450
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a lidé $7 D006801
650    _2
$a macula lutea $x diagnostické zobrazování $7 D008266
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a roztroušená skleróza $x komplikace $x patofyziologie $7 D009103
650    _2
$a prognóza $7 D011379
650    _2
$a nemoci retiny $x diagnostické zobrazování $x etiologie $7 D012164
650    _2
$a neurony sítnice $x patologie $7 D055351
650    _2
$a stupeň závažnosti nemoci $7 D012720
650    _2
$a optická koherentní tomografie $x metody $7 D041623
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Arnow, Sam $u University of California, San Francisco, CA, USA. $7 gn_A_00008760
700    1_
$a Wilson, James A $u University of Pennsylvania, Philadelphia, PA, USA.
700    1_
$a Saidha, Shiv $u Johns Hopkins University, Baltimore, MD, USA.
700    1_
$a Preiningerova, Jana Lizrova $u Charles University, Prague, Czech Republic.
700    1_
$a Oberwahrenbrock, Timm $u Experimental and Clinical Research Center and NeuroCure Clinical Research Center, Charité University Medicine and Max Delbrueck Center for Molecular Medicine, Berlin, Germany.
700    1_
$a Brandt, Alexander U $u Experimental and Clinical Research Center and NeuroCure Clinical Research Center, Charité University Medicine and Max Delbrueck Center for Molecular Medicine, Berlin, Germany.
700    1_
$a Pablo, Luis E $u Hospital Miguel Servet, Zaragoza, Spain.
700    1_
$a Guerrieri, Simone $u San Raffaele Hospital, Milan, Italy.
700    1_
$a Gonzalez, Ines $u Hospital Clinico San Carlos, Madrid, Spain.
700    1_
$a Outteryck, Olivier $u University of Lille, Lille, France.
700    1_
$a Mueller, Ann-Kristin $u University of Düsseldorf, Düsseldorf, Germany.
700    1_
$a Albrecht, Phillip $u University of Düsseldorf, Düsseldorf, Germany. $7 gn_A_00003551
700    1_
$a Chan, Wesley $u University of Calgary, Calgary, AB, Canada.
700    1_
$a Lukas, Sebastian $u University of Zurich, Zurich, Switzerland.
700    1_
$a Balk, Lisanne J $u VU Medical Center, Amsterdam, Netherlands.
700    1_
$a Fraser, Clare $u Save Sight Institute, University of Sydney, NSW, Australia.
700    1_
$a Frederiksen, Jette L $u Glostrup Hospital, University of Copenhagen, Denmark.
700    1_
$a Resto, Jennifer $u Cleveland Clinic Foundation, Cleveland, OH, USA.
700    1_
$a Frohman, Teresa $u University of Texas Southwestern Medical Center, Dallas, TX, USA.
700    1_
$a Cordano, Christian $u University of California, San Francisco, CA, USA.
700    1_
$a Zubizarreta, Irati $u Institut d'Investigacions Biomèdiques August Pi Sunyer (IDIBAPS), Barcelona, Spain.
700    1_
$a Andorra, Magi $u Institut d'Investigacions Biomèdiques August Pi Sunyer (IDIBAPS), Barcelona, Spain. $7 gn_A_00006266
700    1_
$a Sanchez-Dalmau, Bernardo $u Institut d'Investigacions Biomèdiques August Pi Sunyer (IDIBAPS), Barcelona, Spain.
700    1_
$a Saiz, Albert $u Institut d'Investigacions Biomèdiques August Pi Sunyer (IDIBAPS), Barcelona, Spain.
700    1_
$a Bermel, Robert $u Cleveland Clinic Foundation, Cleveland, OH, USA.
700    1_
$a Klistorner, Alexander $u Save Sight Institute, University of Sydney, NSW, Australia.
700    1_
$a Petzold, Axel $u VU Medical Center, Amsterdam, Netherlands; Moorfields Eye Hospital, London, UK.
700    1_
$a Schippling, Sven $u University of Zurich, Zurich, Switzerland.
700    1_
$a Costello, Fiona $u University of Calgary, Calgary, AB, Canada.
700    1_
$a Aktas, Orhan $u University of Düsseldorf, Düsseldorf, Germany. $7 gn_A_00003097
700    1_
$a Vermersch, Patrick $u University of Lille, Lille, France.
700    1_
$a Oreja-Guevara, Celia $u Hospital Clinico San Carlos, Madrid, Spain.
700    1_
$a Comi, Giancarlo $u San Raffaele Hospital, Milan, Italy.
700    1_
$a Leocani, Letizia $u San Raffaele Hospital, Milan, Italy.
700    1_
$a Garcia-Martin, Elena $u Hospital Miguel Servet, Zaragoza, Spain.
700    1_
$a Paul, Friedemann $u Experimental and Clinical Research Center and NeuroCure Clinical Research Center, Charité University Medicine and Max Delbrueck Center for Molecular Medicine, Berlin, Germany.
700    1_
$a Havrdova, Eva $u Charles University, Prague, Czech Republic.
700    1_
$a Frohman, Elliot $u University of Texas Southwestern Medical Center, Dallas, TX, USA.
700    1_
$a Balcer, Laura J $u University of Pennsylvania, Philadelphia, PA, USA; New York University, New York, NY, USA.
700    1_
$a Green, Ari J $u University of California, San Francisco, CA, USA.
700    1_
$a Calabresi, Peter A $u Johns Hopkins University, Baltimore, MD, USA.
700    1_
$a Villoslada, Pablo $u Institut d'Investigacions Biomèdiques August Pi Sunyer (IDIBAPS), Barcelona, Spain; University of California, San Francisco, CA, USA. Electronic address: pvilloslada@clinic.ub.es.
700    1_
$a ,
773    0_
$w MED00006921 $t The Lancet. Neurology $x 1474-4465 $g Roč. 15, č. 6 (2016), s. 574-84
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27011339 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170720 $b ABA008
991    __
$a 20170831103126 $b ABA008
999    __
$a ok $b bmc $g 1239780 $s 985012
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 15 $c 6 $d 574-84 $e 20160318 $i 1474-4465 $m Lancet neurology $n Lancet Neurol $x MED00006921
LZP    __
$a Pubmed-20170720

Najít záznam

Citační ukazatele

Možnosti archivace